In this context, improvements in DNA sequencing may play an even more substantial role in the tailored treatment of NSCLC patients, detecting targetable adaptive mutations in biopsy samples post-progression on a KRAS G12C inhibitor. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.